Chroneme interprets the trajectory before there is a reason to look. Every signal, from every provider, across years. No black box, by design. Intelligence clinicians can question, understand, and trust.
We tested Chroneme on data from 208 hospitals, across 49,850 ICU stays. It detected deterioration more than 35 hours before standard scoring systems flagged anything. When the same engine moved to an independent database, 99.4% of performance was retained.
Zohaib Akhtar is the founder of Chroneme. His cross-disciplinary background spans medicine, public health, biomedical design, business, and AI systems. Also founder of OpenCura. 13 patent families filed.
Chenyu Li, Co-Founder. Adam Wolfe, Co-Founder.
Founded 2025. Chroneme, Inc. 13 patent families filed. Contact: mail@chroneme.com
In 2008 Congress passed GINA, the Genetic Information Nondiscrimination Act. It said a health insurer cannot use your genes to deny you coverage or raise your premium. A prediction about your future health, drawn from your DNA, was placed off-limits to the people who price and ration care.
A trajectory is a prediction of future disease drawn not from your genes but from your data. Kidney function drifting for three years, still inside the normal range, but heading somewhere calculable. It is the exact thing GINA was built to protect, produced by a method the law never imagined and does not cover. The trajectory is the new genome, and nothing treats it as off-limits.
Insurers already weaponize algorithms against patients: Cigna's PXDX system (ProPublica, 2023) and UnitedHealth's nH Predict (STAT News, 2023). Those deny care after the claim. The trajectory enables the version GINA was written to prevent: flagging you before you are ever sick. California's SB 1120 (2024) is a first crack, but it only addresses reactive denial. The genome got a law. The trajectory has not.